Jade Biosciences, Inc.

NASDAQ:JBIO

Biotechnology

Healthcare
$15.49 -1.25%

-$0.21 today

Market cap
$1.07B
Beta
1.45
P/E (TTM)
-7.4
EPS (TTM)
-$2.24
52W Low $6.67High $28.00

Volume 0.79M

Average 0.83M

Returns on capital

Jade Biosciences, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-38.3%

avg -96.5%

ROIC

-34.1%

avg -93.7%

ROA

-36.4%

avg -72.9%

Analysis

ROIC is currently the strongest return metric at -34.1% versus its period average of -93.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Tom Frohlich

President, CEO & DirectorUSD 1.02M5086.33K0.26%

Andrew James King

President of Research & DevelopmentUSD 765.9K46247.50K0.76%

Bradford D. Dahms

CFO & TreasurerUSD 350.05K3737.81K0.12%

Jonathan Quick

Senior Vice President of Finance——83.80K0.26%

Amy Sullivan

Senior Vice President of Development Operations————

Lori Stewart

Senior Vice President of People————

Sandy Lewis

Senior Vice President, Biometrics & Clinical Strategy————

Valerie Fauvelle

Senior Vice President of Regulatory & Quality————

Edward R. Conner

Chief Medical Officer—53——

Elizabeth Balta

Chief Legal Officer & Corporate Secretary—5528.13K0.09%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 12, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Jade Biosciences, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about JBIO's management, answered from reported figures.

Who manages JBIO?

Jade Biosciences, Inc. (JBIO) lists 10 active executives. The top listed executive is Jonathan Quick, Senior Vice President of Finance.

Are JBIO insiders buying or selling?

Recent insider activity shows net buying of $38.34M.